KALA Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect 眼科查看全文
KALA BIO(KALA)2023-01-05 05:18
$Kala制药(KALA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001558370-23-000034 Act: 33 Size: 314 KB 网页链接查看全文
产业链观察2023-04-12 22:54
#药闻简讯# 2023年4月12日,致力于研究、开发和商业化治疗罕见和严重眼疾的创新疗法的临床阶段生物制药公司$Kala制药(KALA)$ 美国食品和药物管理局(FDA)已授予Kala的人类间充质干细胞组(MSC-S)疗法(KPI-012)快速通道指定,用于治疗顽固性角膜上皮缺陷(PCED),这是一种罕见的、使人衰弱的眼部疾病。查看全文
SeekingBiotech2023-04-12 22:51
$Kala制药(KALA)$
KALA Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect 眼科查看全文
一周一次的见面会又来了,还是我→美股风向标。致力于追踪热门美股优质标的,挖掘更多投资机会。接下来我们来看看本周有哪些重要的标的可以关注吧! 1、Kala制药公司 $KALA 表示,FDA接受了其主要候选产品KPI-012——治疗眼睛罕见疾病的研究... 网页链接
智通财经APP获悉,专注于眼部护理的全球医疗专业公司爱尔康(ALC.US)宣布,同意从生物制药公司Kala Pharma(KALA.US)手中收购EYSUVIS(0.25%氯替泼诺混悬滴眼液)和INVELTYS(1%氯替泼诺混悬滴眼液)。 据了解,EYSUVIS是首个也是唯一一个获FD... 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-078325 Size: 11 KB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-078309 Size: 5 KB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-078310 Size: 8 KB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-078287 Size: 5 KB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-078279 Size: 5 KB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-078271 Size: 5 KB 网页链接
$Kala制药(KALA)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0001104659-20-077452 Act: 34 Size: 105 KB 网页链接
$Kala制药(KALA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001104659-20-076852 Act: 33 Size: 158 KB 网页链接
$Kala制药(KALA)$ 内部交易: 2020-06-19,See Remarks,Trachtenberg Eric ,期权,28901普通股, $5.19
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-007674 Size: 6 KB 网页链接